Global Non-Oncology Biologics and Biosimilars Market Size is predicted to witness a 22.0% CAGR during the forecast period for 2025-2034.
Key Industry Insights & Findings from the Report:
Biologics used to treat illnesses other than cancer are known as non-oncology biologics. These medicines are either directly or indirectly derived from living organisms. For inflammatory, infectious, and autoimmune diseases, various biological products are available, such as vaccinations and therapeutic proteins. The term "biosimilar" refers to a class of biologic treatments extremely similar to an already-approved biological product. Their goal is to lower healthcare costs and increase accessibility for patients. Biologics and biosimilars outside of cancer majorly influence contemporary healthcare because they treat a wide range of illnesses and ailments effectively. In contrast, biosimilars provide more affordable alternatives to essential medications, which helps to expand access to these treatments. Furthermore, the increasing number of research and development initiatives aimed at new indications and the upcoming biologic patent expiration. The pout of various formulas and ultimate revenue is funding these research endeavours.
However, the market growth is hampered by the strict regulatory and lack of awareness criteria for the safety and health of non-oncology biologics and biosimilars market and the product's inability to prevent fog in environments with dramatic temperature fluctuations or high humidity non-oncology biologics and biosimilars, Biosimilars and non-oncology biologics have a lengthy and complicated regulatory approval process due to the large amounts of clinical data needed to prove their efficacy and similarity.
Complex manufacturing procedures produce biologics and biosimilars not used in oncology. These processes are only sometimes easy to replicate exactly, which can cause variances in product consistency and quality. One challenge for manufacturers in this sector is maintaining consistent quality. Businesses across all industries felt the effects of the global COVID-19 pandemic and consequent lockdown on their bottom lines. The private healthcare sector was one area where the pandemic made a big splash. The coronavirus pandemic profoundly affected global healthcare corporations' operations, including research and development, manufacturing, and delivery of medicines. Industrial enterprises, except those that produce essential goods, have been shuttered due to the outbreak. Additionally, product supply lines have been disrupted.
The global Non-Ooncology Biologics and Biosimilars Market is segmented based on drug category, application type, and product type. Based on the drug category, the market is segmented into monoclonal antibody, toxins, fusion proteins, insulin, hormones, gene therapy, and cell therapy. By application type, the market is segmented into dermatology, endocrinology, neurology, immunology, respiratory, rheumatology, ophthalmology, and others. By product type, the market is segmented into biologics and biosimilars.
The biologics non-oncology biologics and biosimilars market is expected to lead with a major market share in 2022. Biologics can target specific disease pathways and provide tailored therapy procedures, allowing them to provide potent and specialized therapies for various ailments. The segment's commercial dominance can be attributed to its broad acceptability.
The North American global non-oncology biologics and biosimilars market is expected to record the maximum market share in revenue in the near future. It can be attributed to the high incidence of chronic diseases, and the regulatory framework favours biosimilar approval. Biosimilars and non-oncology biologics are in high demand due to many factors, including a large ageing population and supportive reimbursement policies. In addition, Asia Pacific is estimated to grow rapidly in the global non-oncology biologics and biosimilars market because there are a lot of generic manufacturers in this area. The region's healthcare infrastructure development and increasing elderly population are two additional factors that will drive the market's growth rate.
|
Report Attribute |
Specifications |
|
Growth Rate CAGR |
CAGR of 22.0% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Drug Category, Application Type, Product Type |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Accord Healthcare S.L.U., Alvotech, Amgen, AYUMI Pharmaceutica, Biocon, Biogen, Biosimilar Collaborations Ireland Limited, Boehringer Ingelheim, Celltrion, Cipla, Coherus Biosciences, Cordavis Ltd., Epirus Biopharmaceuticals, Formycon AG, Fresenius Kabi, Glenmark Pharmaceuticals, Hanwha Chemical, Hetero, Innovent Biologics, Kyowa Hakko Kirin (Fujifilm Kyowa Kirin Biologics), LG Chem, Lupin, Mabpharm, Merck, Midas Pharma GmbH, Mylan, Nichi-Iko Pharmaceutical, Organon & Co., Pfizer, Qilu Pharma Spain S.L., Ranbaxy Laboratories (now Sun Pharma), Samsung Bioepis, Sandoz, Shanghai CP Guojian Pharmaceutical, Sorrento Therapeutics (partner), STADA Arzneimittel AG, Sunshine Guojian Pharmaceutical, Synermore, Teva, Torrent Pharmaceuticals, YL Biologics, Zydus Cadila, Other prominent players. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Non-oncology Biologics and Biosimilars Market Snapshot
Chapter 4. Global Non-oncology Biologics and Biosimilars Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Drug Category Estimates & Trend Analysis
5.1. By Drug Category, & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Drug Category:
5.2.1. Monoclonal Antibody
5.2.2. Toxins
5.2.3. Fusion Proteins
5.2.4. Insulin
5.2.5. Hormones
5.2.6. Gene Therapy
5.2.7. Others
Chapter 6. Market Segmentation 2: By Application Type Estimates & Trend Analysis
6.1. By Application Type & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Application Type:
6.2.1. Dermatology
6.2.2. Endocrinology
6.2.3. Neurology
6.2.4. Immunology
6.2.5. Respiratory
6.2.6. Rheumatology
6.2.7. Ophthalmology
6.2.8. Others
Chapter 7. Market Segmentation 3: By Product Type Estimates & Trend Analysis
7.1. By Product Type & Market Share, 2024 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Product Type:
7.2.1. Biologics
7.2.2. Biosimilars
Chapter 8. Non-oncology Biologics and Biosimilars Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Non-oncology Biologics and Biosimilars Market revenue (US$ Million) estimates and forecasts By Drug Category, 2021-2034
8.1.2. North America Non-oncology Biologics and Biosimilars Market revenue (US$ Million) estimates and forecasts By Application Type, 2021-2034
8.1.3. North America Non-oncology Biologics and Biosimilars Market revenue (US$ Million) estimates and forecasts By Product Type, 2021-2034
8.1.4. North America Non-oncology Biologics and Biosimilars Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
8.2. Europe
8.2.1. Europe Non-oncology Biologics and Biosimilars Market revenue (US$ Million) By Drug Category, 2021-2034
8.2.2. Europe Non-oncology Biologics and Biosimilars Market revenue (US$ Million) By Application Type, 2021-2034
8.2.3. Europe Non-oncology Biologics and Biosimilars Market revenue (US$ Million) By Product Type, 2021-2034
8.2.4. Europe Non-oncology Biologics and Biosimilars Market revenue (US$ Million) by country, 2021-2034
8.3. Asia Pacific
8.3.1. Asia Pacific Non-oncology Biologics and Biosimilars Market revenue (US$ Million) By Drug Category, 2021-2034
8.3.2. Asia Pacific Non-oncology Biologics and Biosimilars Market revenue (US$ Million) By Application Type, 2021-2034
8.3.3. Asia Pacific Non-oncology Biologics and Biosimilars Market revenue (US$ Million) By Product Type, 2021-2034
8.3.4. Asia Pacific Non-oncology Biologics and Biosimilars Market revenue (US$ Million) by country, 2021-2034
8.4. Latin America
8.4.1. Latin America Non-oncology Biologics and Biosimilars Market revenue (US$ Million) By Drug Category, (US$ Million) 2021-2034
8.4.2. Latin America Non-oncology Biologics and Biosimilars Market revenue (US$ Million) By Application Type, (US$ Million) 2021-2034
8.4.3. Latin America Non-oncology Biologics and Biosimilars Market revenue (US$ Million) By Product Type, (US$ Million) 2021-2034
8.4.4. Latin America Non-oncology Biologics and Biosimilars Market revenue (US$ Million) by country, 2021-2034
8.5. Middle East & Africa
8.5.1. Middle East & Africa Non-oncology Biologics and Biosimilars Market revenue (US$ Million) By Drug Category, (US$ Million) 2021-2034
8.5.2. Middle East & Africa Non-oncology Biologics and Biosimilars Market revenue (US$ Million) By Application Type, (US$ Million) 2021-2034
8.5.3. Middle East & Africa Non-oncology Biologics and Biosimilars Market revenue (US$ Million) By Product Type, (US$ Million) 2021-2034
8.5.4. Middle East & Africa Non-oncology Biologics and Biosimilars Market revenue (US$ Million) by country, 2021-2034
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Accord Healthcare S.L.U.
9.2.2. Alvotech
9.2.3. Amgen
9.2.4. AYUMI Pharmaceutica
9.2.5. Biocon
9.2.6. Biogen
9.2.7. Biosimilar Collaborations Ireland Limited
9.2.8. Boeheringer Ingelheim
9.2.9. Celltrion
9.2.10. Cipla
9.2.11. Coherus Biosciences
9.2.12. Cordavis Ltd.
9.2.13. Epirus Biopharmaceuticals
9.2.14. Formycon AG
9.2.15. Fresenius Kabi
9.2.16. Glenmark Pharmaceuticals
9.2.17. Hanwha Chemical
9.2.18. Hetero
9.2.19. Innovent Biologics
9.2.20. Kyowa Hakko Kirin (Fujifilm Kyowa Kirin Biologics)
9.2.21. LG Chem
9.2.22. Lupin
9.2.23. Mabpharm
9.2.24. Merck
9.2.25. Midas Pharma GmbH
9.2.26. Mylan
9.2.27. Nichi-Iko Pharmaceutical
9.2.28. Organon & Co.
9.2.29. Pfizer
9.2.30. Qilu Pharma Spain S.L.
9.2.31. Ranbaxy Laboratories (now Sun Pharma)
9.2.32. Samsung Bioepis
9.2.33. Sandoz
9.2.34. Shanghai CP Guojian Pharmaceutical
9.2.35. Sorrento Therapeutics (partner)
9.2.36. STADA Arzneimittel AG
9.2.37. Sunshine Guojian Pharmaceutical
9.2.38. Synermore
9.2.39. Teva
9.2.40. Torrent Pharmaceuticals
9.2.41. YL Biologics
9.2.42. Zydus Cadila
9.2.43. Other prominent players
Non-Oncology Biologics And Biosimilars Market By Drug Category-
Non-Oncology Biologics And Biosimilars Market By Application Type-
Non-Oncology Biologics And Biosimilars Market By Product Type-
Non-Oncology Biologics And Biosimilars Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
